OBJECTIVE: To develop a set of suggested objective performance goals (OPG) for evaluating new catheter-based treatments in critical limb ischemia (CLI), based on evidence from historical controls. METHODS: Randomized, controlled trials of surgical, endovascular, and pharmacologic/biologic treatments for CLI were reviewed according to specified criteria regarding study population and data quality. Line-item data were obtained for selected studies from the sponsor/funding agency. A set of specific outcome measures was defined in accordance with the treatment goals for the CLI population. Risk factors were examined for their influence on key endpoints, and models of stratification based on specific clinical and anatomic variables developed. Sample size estimates were made for single-arm trial designs based on comparison to the suggested OPG. RESULTS: Bypass with autogenous vein was considered the established standard, and data compiled from three individual randomized, controlled trials (N = 838) was analyzed. The primary efficacy endpoint was defined as perioperative (30-day) death or any major adverse limb event (amputation or major reintervention) occurring within one year. Results of open surgery controls demonstrated freedom from the primary endpoint in 76.9% (95% confidence interval [CI] 74.0%-79.9%) of patients at one year, with amputation-free survival (AFS) of 76.5% (95% CI 73.7%-79.5). An additional 3% non-inferiority margin was suggested in generating OPG for catheter-based therapies. Defined clinical (age > 80 years and tissue loss) and anatomic (infra-popliteal anatomy or lack of good quality saphenous vein) risk subgroups provided significantly different point estimates and OPG threshold values. CONCLUSIONS: For new catheter-based therapies in CLI, OPGs offer a feasible approach for pre-market evaluation using non-randomized trial designs. Such studies should incorporate risk stratification in design and reporting as the CLI population is heterogeneous with respect to baseline variables and expected outcomes. Guidelines for CLI trial design to address consistency in study cohorts, methods of assessment, and endpoint definitions are provided.
OBJECTIVE: To develop a set of suggested objective performance goals (OPG) for evaluating new catheter-based treatments in critical limb ischemia (CLI), based on evidence from historical controls. METHODS: Randomized, controlled trials of surgical, endovascular, and pharmacologic/biologic treatments for CLI were reviewed according to specified criteria regarding study population and data quality. Line-item data were obtained for selected studies from the sponsor/funding agency. A set of specific outcome measures was defined in accordance with the treatment goals for the CLI population. Risk factors were examined for their influence on key endpoints, and models of stratification based on specific clinical and anatomic variables developed. Sample size estimates were made for single-arm trial designs based on comparison to the suggested OPG. RESULTS: Bypass with autogenous vein was considered the established standard, and data compiled from three individual randomized, controlled trials (N = 838) was analyzed. The primary efficacy endpoint was defined as perioperative (30-day) death or any major adverse limb event (amputation or major reintervention) occurring within one year. Results of open surgery controls demonstrated freedom from the primary endpoint in 76.9% (95% confidence interval [CI] 74.0%-79.9%) of patients at one year, with amputation-free survival (AFS) of 76.5% (95% CI 73.7%-79.5). An additional 3% non-inferiority margin was suggested in generating OPG for catheter-based therapies. Defined clinical (age > 80 years and tissue loss) and anatomic (infra-popliteal anatomy or lack of good quality saphenous vein) risk subgroups provided significantly different point estimates and OPG threshold values. CONCLUSIONS: For new catheter-based therapies in CLI, OPGs offer a feasible approach for pre-market evaluation using non-randomized trial designs. Such studies should incorporate risk stratification in design and reporting as the CLI population is heterogeneous with respect to baseline variables and expected outcomes. Guidelines for CLI trial design to address consistency in study cohorts, methods of assessment, and endpoint definitions are provided.
Authors: Philip P Goodney; Lori L Travis; Brahmajee K Nallamothu; Kerianne Holman; Bjoern Suckow; Peter K Henke; F Lee Lucas; David C Goodman; John D Birkmeyer; Elliott S Fisher Journal: Circ Cardiovasc Qual Outcomes Date: 2011-12-06
Authors: Michael R Jaff; Christopher J White; William R Hiatt; Gerry R Fowkes; John Dormandy; Mahmood Razavi; Jim Reekers; Lars Norgren Journal: Ann Vasc Dis Date: 2015-10-23
Authors: Peter A Soden; Sara L Zettervall; Thomas Curran; Ageliki G Vouyouka; Philip P Goodney; Joseph L Mills; John W Hallett; Marc L Schermerhorn Journal: J Vasc Surg Date: 2016-09-28 Impact factor: 4.268
Authors: Courtney J Warner; Spencer W Greaves; Robin J Larson; David H Stone; Richard J Powell; Daniel B Walsh; Philip P Goodney Journal: J Vasc Surg Date: 2014-01-24 Impact factor: 4.268
Authors: Sanjay Misra; Robert Lookstein; John Rundback; Alan T Hirsch; William R Hiatt; Michael R Jaff; Christopher R White; Michael Conte; Patrick Geraghty; Manesh Patel; Kenneth Rosenfield Journal: J Vasc Interv Radiol Date: 2013-04 Impact factor: 3.464